ArticleJournal of gastrointestinal cancer2023

Comparative Outcomes of Second-line Topoisomerase-I Inhibitor Therapies on Neuroendocrine Carcinoma.

Ho-Man Yeung et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.